NEXGEL to Pay $15M Upfront for Biomaterials Portfolio, Triples Revenue
NEXGEL will pay $15 million upfront and up to $20 million in milestone payments to license and acquire six commercial-stage regenerative biomaterial products from Celularity. The deal is expected to triple NEXGEL’s annual revenue to about $35 million and render the company profitable immediately upon closing.
1. Deal Terms and Consideration
NEXGEL will pay $15 million upfront and may pay up to $20 million in milestone payments based on annual net sales targets to license and acquire six commercial-stage regenerative biomaterial products from Celularity, subject to customary closing processes and financing.
2. Revenue and Profitability Impact
The transaction is expected to approximately triple NEXGEL’s annual revenue from current levels to about $35 million and deliver immediate profitability upon closing, marking the most significant milestone in the company’s history.
3. Portfolio Details
The acquired portfolio comprises six products with over a decade of clinical use in tendon repair, skin grafting, and bone growth, each supported by demonstrated clinical utility and existing insurance reimbursement pathways.
4. Strategic Expansion
The deal is projected to bring an experienced commercial and scientific team to NEXGEL, enhancing its capabilities and reach in the regenerative biomaterials market and broadening its footprint in the medical technology sector.